<?xml version='1.0' encoding='utf-8'?>
<document id="31732698"><sentence text="Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222." /><sentence text="Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease in Caucasians caused by pathogenic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR)" /><sentence text=" Significant small molecule therapeutic advances over the past two decades have been made to target the defective CFTR protein and enhance its function" /><sentence text=" To address the most prevalent defect of the defective CFTR protein (i" /><sentence text="e" /><sentence text=", F508del mutation) in CF, two biomolecular activities are required, namely, correctors to increase the amount of properly folded F508delCFTR levels at the cell surface and potentiators to allow the effective opening, i" /><sentence text="e" /><sentence text=", function of the F508delCFTR channel" /><sentence text=" Combined, these activities enhance chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance"><entity charOffset="36-48" id="DDI-PubMed.31732698.s9.e0" text="chloride ion" /></sentence><sentence text=" To enhance clinical benefits to CF patients, a complementary triple combination therapy consisting of two corrector molecules, type 1 (C1) and type 2, with additive mechanisms along with a potentiator are being investigated in the clinic for maximum restoration of mutated CFTR function" /><sentence text=" We report the identification and in vitro biologic characterization of ABBV-2222/GLPG2222 (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid),-a novel, potent, and orally bioavailable C1 corrector developed by AbbVie-Galapagos and currently in clinical trials-which exhibits substantial improvements over the existing C1 correctors"><entity charOffset="92-233" id="DDI-PubMed.31732698.s11.e0" text="4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid" /></sentence><sentence text=" This includes improvements in potency and drug-drug interaction (DDI) compared with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (VX-809, Lumacaftor) and improvements in potency and efficacy compared with 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (VX-661, Tezacaftor)"><entity charOffset="85-189" id="DDI-PubMed.31732698.s12.e0" text="3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid" /><entity charOffset="191-197" id="DDI-PubMed.31732698.s12.e1" text="VX-809" /><entity charOffset="199-209" id="DDI-PubMed.31732698.s12.e2" text="Lumacaftor" /><entity charOffset="266-415" id="DDI-PubMed.31732698.s12.e3" text="1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e0" e2="DDI-PubMed.31732698.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e0" e2="DDI-PubMed.31732698.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e0" e2="DDI-PubMed.31732698.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e0" e2="DDI-PubMed.31732698.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e1" e2="DDI-PubMed.31732698.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e1" e2="DDI-PubMed.31732698.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e1" e2="DDI-PubMed.31732698.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e2" e2="DDI-PubMed.31732698.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31732698.s12.e2" e2="DDI-PubMed.31732698.s12.e3" /></sentence><sentence text=" ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value &lt;10 nM" /><sentence text=" SIGNIFICANCE STATEMENT: To address the most prevalent defect of the defective CFTR protein (i" /><sentence text="e" /><sentence text=", F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein" /><sentence text=" ABBV-2222/GLPG2222, which is currently in clinical trials, exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR and substantial improvements over the existing C1 correctors" /><sentence text="" /></document>